Claybrook Capital, LLC Fate Therapeutics Inc Transaction History
Claybrook Capital, LLC
- $172 Million
- Q3 2023
Shares
2 transactions
Others Institutions Holding FATE
# of Institutions
175Shares Held
115MCall Options Held
53.7KPut Options Held
9K-
Redmile Group, LLC San Francisco, CA13.2MShares$31.9 Million3.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.4MShares$25.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$24.5 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.57MShares$13.5 Million0.72% of portfolio
-
State Street Corp Boston, MA5.25MShares$12.7 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $235M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...